bs-15569R

[Primary Antibody]

BIOSS ANTIBODIES

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

IGFBPL1 Rabbit pAb

- DATASHEET -

Host: Rabbit Isotype: IgG

Clonality: Polyclonal

GenelD: 347252 **SWISS:** Q8WX77

Target: IGFBPL1

Immunogen: KLH conjugated synthetic peptide derived from human IGFBPL1:

201-278/278.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50%

Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

Background: IGFBPL1 is a secreted IGF (Insulin-like growth factor) binding protein that is known to contain an Ig-like C2-type

protein that is known to contain an ig-like C2-type (immunoglobulin-like) domain, an IGFBP N-terminal domain and a

Kazal-like domain. IGF-binding proteins characteristically act to extend the half-life of IGFs and may influence the growth promoting effects of the IGFs. The interaction of IGFBPs with IGFs can affect cell surface receptors, specifically, IGFBPs may enhance or decrease a cells insulin sensitivity. IGFBPL1 has been found to be down-regulated in multiple tumors and thus may be a likely tumor suppressor candidate. Highly expressed in both brain and testis, IGFBPL1 is found at lower levels in the prostate, bladder and

lung.

Applications: IHC-P (1:100-500)

IHC-F (1:100-500) IF (1:100-500) ELISA (1:5000-10000)

Reactivity: (predicted: Human, Mouse,

Rat, Pig, Sheep, Cow, Dog,

Horse)

Predicted MW.: 26 kDa

Subcellular Location: Secreted

- SELECTED CITATIONS -

• [IF=5.496] Yang Y et al. Epigenetic silencing of IGFBPL1 promotes esophageal cancer growth by activating PI3K-AKT signaling. Clin Epigenetics. 2020 Feb 10;12(1):22. IHC; Human. 32041673